Physician profile
Corey Danielle Webb
NPI 1265985584
$5,767.34
in general payments reported to CMS, 2019-2025
25 companies · $985 in 2025
The $985 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,086 · 2022: $1,133 · 2023: $1,415 · 2024: $1,148 · 2025: $985.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,548.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,547.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,112.03 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Abbvie INC. | $1,083.67 | 2021-2025 | |
| Lilly USA, LLC | $793.81 | 2021-2025 | Mounjaro, Jardiance, Trulicity |
| Pfizer INC. | $482.21 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $311.19 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $255.07 | 2021-2025 | Jardiance |
| Abbott Laboratories | $235.58 | 2021-2022 | |
| Astellas Pharma US INC | $206.01 | 2022-2024 | Veozah, Myrbetriq |
| Amgen INC. | $181.96 | 2023-2025 | Otezla, Repatha, Repatha |
| Nestle Healthcare Nutrition INC. | $155.40 | 2021-2023 | |
| Exact Sciences Corporation | $134.67 | 2023-2025 | Cologuard Collection Kit |
| Xeris Pharmaceuticals, INC. | $132.75 | 2023-2025 | Gvoke Hypopen |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $118.48 | 2023-2025 | Xifaxan, Trulance |
| Novo Nordisk INC | $95.42 | 2022-2025 | |
| Mylan Specialty L.P. | $87.92 | 2021-2024 | Yupelri |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $86.54 | 2022-2023 | |
| Aimmune Therapeutics, INC. | $73.06 | 2024-2025 | Zenpep |
| Biohaven Pharmaceuticals, INC. | $54.22 | 2021 | |
| Alkermes, INC. | $40.36 | 2021-2022 | |
| Dexcom, INC. | $30.64 | 2021-2022 | |
| Amarin Pharma, INC. | $24.35 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $23.46 | 2025 | Caplyta |
| Phathom Pharmaceuticals, INC. | $22.40 | 2024 | Voquezna |
| Evoke Pharma, INC. | $13.22 | 2023 | Gimoti |
| Glaxosmithkline, LLC. | $12.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Corey Webb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.